

building a global oncology company

novocure®

NASDAQ: NVCR

In 2000 Novocure developed its innovative therapy Tumor Treating Fields (TTFields). Even after 20 years of innovation, it is only the beginning.

Novocure has a growing commercial business

17,000⁺

PATIENTS TREATED TO DATE

1000⁺

EMPLOYEES WORLDWIDE


4

INDICATIONS IN LATE-STAGE PIPELINE

3

FDA APPROVED INDICATIONS

Yoram Palti, our founder and professor emeritus of physiology and biophysics at the Technion - Israel institute of technology, sought to leverage his expertise in biophysics to develop a new way to treat solid tumor cancers that would destroy tumor cells while sparing healthy tissue and avoiding many of the life-altering side effects of existing cancer therapies.



Professor Yoram Palti,
Founder

Novocure corporate timeline

Since our founding, we have reached many key milestones.

2000

Professor Yoram Palti, M.D. Ph.D., founds Novocure

2009

Phase 3 pivotal EF-14 trial opens

2015

U.S. FDA approves TTFields for newly diagnosed glioblastoma add in combination with chemotherapy

2019

U.S. FDA approves TTFields for MPM under HDE in combination with chemotherapy

2006

Phase 3 pivotal EF-11 trial opens

2011

U.S. FDA approves TTFields for recurrent glioblastoma

2016

U.S. FDA approves second generation TTFields System for GBM

striving to extend survival in some of the most aggressive forms of cancer worldwide

TFields therapy is a foundational platform, enabling our efforts to make a difference in cancer. We are focused on growing our organization to bring TFields therapy to as many patients who can benefit. Beyond our ongoing preclinical, clinical, and commercial efforts, we believe there is a considerable opportunity to improve the usability of TFields through product innovation. We believe we are just beginning our journey.

“The ability to make it smaller and lighter is such a benefit to make the treatment more accessible, the second generation system is a symbol of what we can do and a precursor of things to come.”

– **Mike Ambrogio**,
Senior Technology Officer,
Former Chief Operating Officer

Original system



Second generation system



our values: **INNOVATION** **FOCUS** **DRIVE** **COURAGE** **TRUST** **EMPATHY**

global active markets*



*as of June 2020

**Partnership with Zai Lab

executive leadership

William F. Doyle
Executive Chairman

Asaf Danziger
Chief Executive Officer

Yoram Palti, M.D., Ph.D.
Founder

Ely Benaim, M.D.
Chief Medical Officer

Ashley Cordova
Chief Financial Officer

Wilco Groenhuisen
Chief Operating Officer

Frank Leonard
Chief Development Officer

Todd Longworth
General Counsel

Pritesh Shah
Chief Commercial Officer

Uri Weinberg, M.D., Ph.D.
Chief Science Officer

novocure[®]
patientforward

For more information,
visit [novocure.com](https://www.novocure.com)

©2020 Novocure. All rights reserved.
Novocure is a trademark of
Novocure. US-OPT-03689v3.0
December 2020